American Association for Cancer Research Release: PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the Provectus Pharmaceuticals Inc. Annual Meeting

Published: Apr 09, 2013

Provectus Pharmaceuticals, Inc. (OTCQB: PVCT,, a development-stage oncology and dermatology biopharmaceutical company, announced that a poster presentation detailing the induction of tumor specific immunity after intralesional PV-10 treatment was presented by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.

Back to news